Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 08, 2008. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction involving Mr. S M Bicknell, who acquired a beneficial interest in 9 Ordinary shares on July 07, 2008. This acquisition resulted from the re-investment of dividends under a Personal Equity Plan at a price of £11.59 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 07, 2008
- Individual: Mr. S M Bicknell
- Shares Acquired: 9 Ordinary shares
- Transaction Type: Dividend re-investment via Personal Equity Plan
- Price per Share: £11.59
- Notification Date: July 08, 2008